Abstract:Palladium and platinum complexes, especially those that include cisplatin, can be useful chemotherapeutic drugs. Alternatives that have less adverse effects and require lower dosages of treatment could be provided by complexes containing pyridine bases. The complexes [Pd(SCN) 2 (4-Acpy) 2 ] (1), [Pd(N 3 ) 2 (4-Acpy) 2 ] (2) [Pd(paOH) 2 ].2Cl ( 3 ) and [Pt(SCN) 2 (paO) 2 ] (4) were prepared by self-assembly method at ambient temperature; (4-Acpy = 4-acetylpyridine and paOH = pyridine-2-carbaldehyde-oxime). The structure of complexes 1–4 was confirmed using spectroscopic and X-ray crystallography methods. Complexes 1–4 have similar features in isomerism that include the trans coordination geometry of pyridine ligands with Pd or Pt ion. The 3D network structure of complexes 1–4 was constructed by an infinite number of discrete mononuclear molecules extending via H-bonds. The Pd and Pt complexes 1–4 with pyridine ligands were assessed on MCF-7, T47D breast cancer cells and HCT116 colon cancer cells. The study evaluated cell death through apoptosis and cell cycle phases in MCF-7 cells treated with palladium or platinum conjugated with pyridine base. Upon treatment of MCF-7 with these complexes, the expression of apoptotic signals (Bcl2, p53, Bax and c-Myc) and cell cycle signals (p16, CDK1A, CDK1B) were evaluated. Compared to other complexes and cisplatin, IC 50 of complex 1 was lowest in MCF-7 cells and complex 2 in T47D cells. Complex 4 has the highest effectiveness on HCT116. The selective index (SI) of complexes 1–4 has a value of more than two for all cancer cell lines, indicating that the complexes were less toxic to normal cells when given the same dose. MCF-7 cells treated with complex 2 and platinum complex 4 exhibited the highest level of early apoptosis. p16 may be signal arrest cells in Sub G, which was observed in cells treated with palladium complexes that suppress excessive cell proliferation. High c-Myc expression of treated cells with four complexes 1–4 and cisplatin could induce p53. All complexes 1–4 elevated the expression of Bax and triggered by the tumor suppressor gene p53. p53 was downregulating the expression of Bcl2.

Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase II in cancer cells

Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase IIα in cancer cells

DNA topoisomerases as additional targets for anticancer monofunctional platinum( ii ) complexes

Cellular and Biomolecular Responses of Human Ovarian Cancer Cells to Cytostatic Dinuclear Platinum(ii) Complexes

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand

Palladium and platinum complexes based on pyridine bases induced anticancer effectiveness via apoptosis protein signaling in cancer cells

Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity

Platinum(IV) Complexes Conjugated with Phenstatin Analogue As Inhibitors of Microtubule Polymerization and Reverser of Multidrug Resistance.

Dna Cross-Linking Patterns Induced by an Antitumor-Active Trinuclear Platinum Complex and Comparison with Its Dinuclear Analogue

Synthesis and Anticancer Activity of [2-Hydroxy-1,3-diaminopropane-κ2n,n′] Platinum(ii) Complexes

Synthesis and DNA Interactions Study of Novel Fluorinated Pyridinium Platinum (IV) Complexes with Tumor Targeting Activity

Antiproliferative Activity of Platinum(II) and Copper(II) Complexes Containing Novel Biquinoxaline Ligands

Dual-target platinum(IV) complexes exhibit antiproliferative activity through DNA damage and induce ER-stress-mediated apoptosis in A549 cells

Anticancer Effect of PtIIPHEN SS, PtII5ME SS, PtII56ME SS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer

Pt(IV) Prodrugs Containing Microtubule Inhibitors Displayed Potent Antitumor Activity and Ability to Overcome Cisplatin Resistance.

A monofunctional trinuclear platinum complex with steric hindrance demonstrates strong cytotoxicity against tumor cells.

Anticancer Potency of Platinum(Ii) Complexes Containing Both Chloride Anion and Chelated Carboxylate As Leaving Groups

Unique Dna Binding Mode Of Antitumor Trinuclear Tridentate Platinum(Ii) Compound

Dual–target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP–ribose) polymerase (PARP–1) and enhancing DNA damage

Fresh platinum complexes with promising antitumor activity.